- Conditions
- Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16
- Interventions
- PVX4 Combination Product, Placebo Control
- Combination Product · Other
- Lead sponsor
- PapiVax Biotech, Inc.
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- The Bronx, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–22
of 22
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Back Pain
- Interventions
- Buprenorphine transdermal patch, Placebo oxycodone/acetaminophen tablets, OXY/APAP, Placebo transdermal patch (TDS)
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1998
- U.S. locations
- 12
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Gainesville, Florida + 7 more
- Conditions
- Back Pain
- Interventions
- Buprenorphine transdermal delivery system
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1998
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Gainesville, Florida • Plantation, Florida + 8 more
- Conditions
- Low Back Pain
- Interventions
- Buprenorphine transdermal system, Placebo
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 539 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 86
- States / cities
- Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 71 more
- Conditions
- Motion Sickness
- Interventions
- scopolamine HBr, Transdermal Scopolamine
- Drug
- Lead sponsor
- Repurposed Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Dayton, Ohio
- Conditions
- Skin Irritation, Sensitization
- Interventions
- Donepezil TDS, Vehicle TDS
- Drug
- Lead sponsor
- Corium, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Lincoln, Nebraska
- Conditions
- Postoperative Pain
- Interventions
- Buprenorphine transdermal delivery system
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 1997
- U.S. locations
- 1
- States / cities
- Plantation, Florida
- Conditions
- Hemorrhagic Fever With Renal Syndrome
- Interventions
- HTNV/PUUV DNA vaccine, Placebo, TriGrid Delivery System (TDS)
- Biological · Device
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- HIV Infections
- Interventions
- HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
- Biological · Device
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 5
- States / cities
- New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Motion Sickness
- Interventions
- DPI-386 Nasal Gel, Placebos
- Drug
- Lead sponsor
- Repurposed Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- HIV, Therapeutic Vaccine
- Interventions
- rVSV, IL-12 pDNA adjuvant, HIV-Mag pDNA, Placebo
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness
- Interventions
- Scopolamine Transdermal Patch [Transderm Scop], Scopolamine, Placebo Patch, Placebo Gel
- Drug
- Lead sponsor
- Naval Aeromedical Research Unit, Dayton
- Federal
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Dayton, Ohio
- Conditions
- Healthy
- Interventions
- granisetron
- Drug
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Motion Sickness
- Interventions
- DPI-386 Nasal Gel, DPI-386 Placebo Nasal Gel, Transderm Scop®
- Drug
- Lead sponsor
- Repurposed Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Dayton, Ohio
- Conditions
- Chalazion
- Interventions
- SUN-131 1.5% TDS, Placebo TDS
- Drug
- Lead sponsor
- Senju USA, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 6
- States / cities
- Santa Ana, California • Littleton, Colorado • Washington D.C., District of Columbia + 3 more
- Conditions
- HIV Infections
- Interventions
- p24CE1/2 pDNA Vaccine, p55^gag pDNA Vaccine, IL-12 pDNA Adjuvant, Placebo, Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
- Biological · Device
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- San Francisco, California • Decatur, Georgia • Cleveland, Ohio
- Conditions
- HIV Infections
- Interventions
- HIV-1 nef/tat/vif, env pDNA vaccine, rVSV HIV envC vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Healthy Volunteers
- Interventions
- Buprenorphine transdermal patch, Matching placebo transdermal patch, Avelox (moxifloxacin hydrochloride) tablet
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Chalazion
- Interventions
- SUN-131 1.5% TDS, Placebo TDS
- Drug
- Lead sponsor
- Senju USA, Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 65
- States / cities
- Chandler, Arizona • Prescott, Arizona • Sun City, Arizona + 56 more
- Conditions
- Motion Sickness
- Interventions
- Scopolamine Nasal Gel, Placebo
- Drug · Other
- Lead sponsor
- Repurposed Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- ECG Effects
- Interventions
- Buprenorphine transdermal patch, Naltrexone tablet, Placebos (for TDS and for naltrexone and for moxifloxacin), Moxifloxacin tablet
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 328 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Postoperative Pain
- Interventions
- Buprenorphine transdermal patch, Placebo BTDS
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • San Clemente, California • Orlando, Florida + 2 more